Wells Fargo Maintains Equal-Weight on Cabaletta Bio, Lowers Price Target to $3
Wells Fargo analyst Derek Archila maintains Cabaletta Bio (NASDAQ:CABA) with a Equal-Weight and lowers the price target from $4 to $3.
Read original at benzingaStocks · News reference
8-K filing — Cabaletta Bio, Inc. (CABA)
Filed: 2026-08-13 AccNo: 0001759138-26-000038 Size: 322 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Aug 13, 2026, 11:32 AM
- Checked
- Aug 13, 2026, 11:32 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Cabaletta Bio Q2 EPS $(0.34) Beats $(0.39) Estimate
Cabaletta Bio (NASDAQ:CABA) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.39) by 12.82 percent. This is a 53.42 percent increase over losses of $(0.73) per share from
Read original at benzinga